Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 2
1995 1
1997 2
1999 2
2002 1
2005 2
2006 1
2008 1
2009 1
2010 1
2011 5
2012 2
2015 1
2016 2
2017 1
2018 1
2019 1
2020 1
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Advances in the Treatment of Hairy Cell Leukemia Variant.
Tran J, Gaulin C, Tallman MS. Tran J, et al. Curr Treat Options Oncol. 2022 Jan;23(1):99-116. doi: 10.1007/s11864-021-00927-z. Epub 2022 Feb 18. Curr Treat Options Oncol. 2022. PMID: 35178674 Review.
Hairy cell leukemia variant (HCL-V) is a rare B cell lymphoproliferative disorder with a clinical-pathological distinction from the classic form of hairy cell leukemia (HCL-C). ...
Hairy cell leukemia variant (HCL-V) is a rare B cell lymphoproliferative disorder with a clinical-patholo …
Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J, Maitre E, Troussard X. Paillassa J, et al. Curr Oncol Rep. 2022 Sep;24(9):1133-1143. doi: 10.1007/s11912-022-01285-1. Epub 2022 Apr 11. Curr Oncol Rep. 2022. PMID: 35403971 Review.
These findings led to the development of new targeted therapies which have shown interesting results in recent clinical trials. HCL is a chronic B-cell lymphoproliferative disorder. ...
These findings led to the development of new targeted therapies which have shown interesting results in recent clinical trials. HCL i …
Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.
Robak T. Robak T. Cancer Treat Rev. 2011 Feb;37(1):3-10. doi: 10.1016/j.ctrv.2010.05.003. Epub 2010 Jun 16. Cancer Treat Rev. 2011. PMID: 20558005 Review.
Hairy-cell leukemia variant (HCl-V) is a district clinico-pathological entity with intermediate features between classical HCl (HCl-C) and B-cell prolymphocytic leukemia. ...
Hairy-cell leukemia variant (HCl-V) is a district clinico-pathological entity with intermediate features between …
Management of hairy cell leukemia variant.
Robak T. Robak T. Leuk Lymphoma. 2011 Jun;52 Suppl 2:53-6. doi: 10.3109/10428194.2011.566392. Leuk Lymphoma. 2011. PMID: 21599606 Review.
Hairy cell leukemia variant (HCL-V) is now included in the World Health Organization (WHO) classification as a provisional entity and is no longer considered to be biologically related to classic HCL (HCL-C). ...Patients with HCL-V treated with pentost …
Hairy cell leukemia variant (HCL-V) is now included in the World Health Organization (WHO) classification as a p …
Potential breakthroughs with investigational drugs for hairy cell leukemia.
Robak T, Wolska A, Robak P. Robak T, et al. Expert Opin Investig Drugs. 2015;24(11):1419-31. doi: 10.1517/13543784.2015.1081895. Epub 2015 Sep 2. Expert Opin Investig Drugs. 2015. PMID: 26329588 Review.
AREAS COVERED: This article summarizes recent investigational therapies of HCL, looking at their: mechanism of action, pharmacological properties, clinical activity and toxicity, as well as their emerging role in its treatment. ...EXPERT OPINION: The use of vemurafenib and …
AREAS COVERED: This article summarizes recent investigational therapies of HCL, looking at their: mechanism of action, pharmacological prope …
Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F, Visentin A, Schirinzi E, Salvalaggio A, Cacciavillani M, Candiotto C, Baratè C, Cellini A, Bertorelle R, Siciliano G, Trentin L, Briani C. Castellani F, et al. Neurol Neuroimmunol Neuroinflamm. 2023 May 3;10(4):e200122. doi: 10.1212/NXI.0000000000200122. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37137530 Free PMC article.
Among them, 38 (50.7%) had IgM monoclonal gammopathy of undetermined significance, 29 (38.7%) Waldenstrom macroglobulinemia (WM), and 8 (10.6%) chronic lymphocytic leukemia/marginal zone lymphoma/hairy cell leukemia variant. Molecular analysis was perf …
Among them, 38 (50.7%) had IgM monoclonal gammopathy of undetermined significance, 29 (38.7%) Waldenstrom macroglobulinemia (WM), and 8 (10. …
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC, Kabel CC, Pappacena JJ, Stump SE, Daley RJ. King AC, et al. Ann Pharmacother. 2019 Sep;53(9):922-932. doi: 10.1177/1060028019836775. Epub 2019 Mar 6. Ann Pharmacother. 2019. PMID: 30841702 Review.
An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox. …
An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, …
Refractory hairy cell leukemia-variant.
Hu Z, Sun Y, Wang W, Medeiros LJ, Kanagal-Shamanna R. Hu Z, et al. Am J Hematol. 2017 Dec;92(12):1398-1399. doi: 10.1002/ajh.24580. Epub 2016 Nov 12. Am J Hematol. 2017. PMID: 27727469 Free article. No abstract available.
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Wang Y, Wang T, Yu Y, Wang Q, Yan Y, Li R, Sun Q, Xiong W, Lyu R, Yu Z, Liu W, Sui W, Huang W, Wang H, Li C, Wang J, Zou D, An G, Wang J, Qiu L, Yi S. Wang Y, et al. Ann Hematol. 2022 Jun;101(6):1201-1210. doi: 10.1007/s00277-022-04795-x. Epub 2022 Apr 18. Ann Hematol. 2022. PMID: 35437610
Both characteristics and optimal treatment strategy for hairy cell leukemia-variant (HCL-v) remain elusive due to its rarity. We retrospectively analyzed the clinical features of HCL-v and the efficacy of first-line treatment options in a large …
Both characteristics and optimal treatment strategy for hairy cell leukemia-variant (HCL-v) remain elusive due t …
33 results